Susanne Gräslund did her doctoral training in Biotechnology at the Royal Institute of Technology in Stockholm, Sweden, developing the concepts for what later became the Human Protein Atlas Project. After her dissertation in 2002 she worked for three years at Biovitrum AB in the Target Expression & Purification section. In March 2005, Susanne joined the newly started Structural Genomics Consortium group in Stockholm, heading the Biotechnology team responsible for the generic protein production pipeline. She was then recruited to the SGC Toronto site as Principal Investigator for the Biotechnology team in September 2011 and to manage the SGC efforts to make recombinant antibodies to SGC target proteins. In 2015, SGC established a new lab at Karolinska Institutet in Stockholm, funded by Innovative Medicines Initiative where Dr. Gräslund is now heading the Recombinant antibodies group.
At the SGC, Susanne has mainly worked with the biotechnology groups at several sites, developing methods for high-throughput production of human proteins for crystallization and to be used as antigens for the generation of recombinant antibodies. She now heads the Recombinant antibodies group at SGC Karolinska, which generates recombinant antibodies to selected SGC target proteins. Her group is currently funded by the IMI project ULTRA-DD, and focus is to generate antibodies to target proteins involved in inflammatory processes and autoimmune disease.